Company Encyclopedia
View More
name
Oculis Holding AG
OCS.US
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
4.609 T
OCS.USMarket value -Rank by Market Cap -/-

Financial Score

19/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking131/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-92.19%E
    • Profit Margin-13160.30%E
    • Gross Margin-5709.47%E
  • Growth ScoreD
    • Revenue YoY-5.97%D
    • Net Profit YoY-54.28%D
    • Total Assets YoY40.86%A
    • Net Assets YoY44.57%A
  • Cash ScoreD
    • Cash Flow Margin-0.76%D
    • OCF YoY-5.97%D
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio22.19%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

    Top Wall Street analysts initiated coverage on several companies with positive ratings. Keybanc's Michael Leshock rated AeroVironment (AVAV) as Overweight with a $285 target, while BTIG's Gregory Lewis rated Capital Clean Energy Carriers (CCEC) as Buy with a $25 target. Other initiations include Arthur J. Gallagher & Co. (AJG) by Morgan Stanley, Walker & Dunlop (WD) by Jefferies, and Oculis Holding AG (OCS) by JP Morgan, all with favorable ratings and price targets.

    benzinga_article·
    US
    AVAV
    +2.68%
    US
    OCS
    +6.96%
    benzinga_article·
    US
    AVAV
    +2.68%
    US
    OCS
    +6.96%

    Oculis in Switzerland announces notifications regarding vesting and settlement of RSUs granted to directors.

    On December 9, 2025, in Zug, Switzerland, notifications were issued regarding the vesting and settlement of Restricted Stock Units (RSUs) that were previously awarded to the directors of the company. The notifications pertain to the allocation of company shares as part of the RSUs' vesting process.

    Unusual Whales·
    US
    OCS
    +6.96%
    Unusual Whales·
    US
    OCS
    +6.96%

    Oculis Holding AG Announces Disclosure of Directors' RSU Transactions

    Oculis Holding AG announced the vesting and settlement of RSUs for directors Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner. The disclosures detail recent transactions by these directors. The original content was published via GlobeNewswire on December 09, 2025.

    Reuters·
    US
    OCS
    +6.96%
    Reuters·
    US
    OCS
    +6.96%

    Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited | VTRS Stock News

    Oculis Holding AG announced its participation in upcoming ophthalmology events, including Eyecelerator and the AAO Annual Meeting, where they will highlight their innovative late-stage pipeline. Key updates include the acceleration of Privosegtor into registrational trials for optic neuritis, updates on the Phase 3 DIAMOND program for diabetic macular edema, and the PREDICT-1 trial for dry eye disease. Oculis will also participate in Innovate Retina, SAIVO, and the COPhy Satellite Symposium.

    StockTitan·
    US
    OCS
    +6.96%
    US
    VTRS
    +0.08%
    StockTitan·
    US
    OCS
    +6.96%
    US
    VTRS
    +0.08%

    Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | OCS Stock News

    11/28/2025 - 04:05 PM ZUG, Switzerland, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' transaction - Arshad Khanani - 25 November 2025 RSU vest

    StockTitan·
    US
    OCS
    +6.96%
    StockTitan·
    US
    OCS
    +6.96%
    © 2025 Longbridge｜Disclaimer